Sanofi reports amlitelimab improved lung function in asthma, with new phase 3 trials planned across its respiratory pipeline.

This covalent binding is fully reversible upon denaturation of the protein. Functionally, rilzabrutinib suppresses anti-IgM-induced human B-cell proliferation and inhibits CD69 expression on B ...

Sanofi has not had the success it was hoping for with its oral BTK inhibitors, acquired as part of its $3.7 billion buyout of Principia Biopharma, but can now point to a win for rilzabrutinib in ...

already a $12 billion blockbuster in other indications – as well as Sanofi’s rival oral BTK inhibitor rilzabrutinib, which showed promise in a mid-stage trial and is heading for phase 3 trials ...

With UPLIZNA receiving a label expansion that opens the door to a previously untapped rare disease market, Amgen is seeing strong returns on its USD 27.8 billion acquisition of Horizon ...

A scientific statement regarding cardiovascular toxicity in patients with history of treatment for childhood cancer has been published by the AHA. Updated guidance for managing cardiovascular ...

In this younger patient population, diazepam nasal spray was readily absorbed and demonstrated a consistent PK profile with that of older children and adults aged 6 to 59 years. The Food and Drug ...

Approval of Opdivo plus Yervoy combination was based on results from the Phase III CheckMate-9DW trial, which demonstrated significantly improved overall survival and overall response rate in patients ...

An estimated record-high 91 million Americans are unable to pay for quality health care if they needed it today, according to a new West Health and Gallup survey. Crystal L. Mackall, MD, renowned ...